RANKL Antibody (12A380): sc-59982
- RANKL Antibody (12A380) is a mouse monoclonal IgG1, cited in 5 publications, provided at 100 µg/ml
- raised against amino acids 1-317 of RANKL of mouse origin
- recommended for detection of RANKL of mouse, rat and human origin by WB, IF and FCM
- available conjugated to phycoerythrin for IF, IHC(P) and FCM
- See RANKL (G-1): sc-377079 for RANKL antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for RANKL Antibody (12A380). This work is in progress.
QUICK LINKS
RANKL Antibody (12A380) is a mouse monoclonal IgG1 antibody raised against amino acids 1-317 of RANKL of mouse origin, effectively detecting RANKL proteins from mouse, rat, and human origins by western blotting (WB), immunofluorescence (IF), and flow cytometry (FCM). RANKL, also known as Receptor Activator of Nuclear Factor Kappa-B Ligand, TNFSF11, TRANCE, OPGL, or ODF, is a type II transmembrane protein primarily expressed on the surface of osteoblasts, stromal cells, and activated T cells. RANKL (12A380) antibody localizes to the cell membrane, which is crucial for facilitating cell-to-cell interactions, particularly the binding to RANK receptor on osteoclast precursors and dendritic cells. This membrane-bound interaction activates essential signaling pathways such as NF-κB and JNK, leading to osteoclast differentiation and activation, which are vital for bone remodeling and immune system regulation. Dysregulation of RANKL expression or function can result in pathological conditions like osteoporosis, rheumatoid arthritis, and bone metastasis, underscoring its importance in maintaining skeletal integrity and immune homeostasis. RANKL monoclonal antibody (12A380) can advance the understanding of bone metabolism disorders and immune-related diseases, aiding in the development of therapeutic interventions. Anti-RANKL antibody (12A380) serves as an essential resource for studies involving osteoclast biology, T cell regulation, and related pathological conditions.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
RANKL Antibody (12A380) References:
- Role of the RANK/RANKL Pathway in Multiple Myeloma. | Raje, NS., et al. 2019. Clin Cancer Res. 25: 12-20. PMID: 30093448
- Coupling of bone resorption and formation by RANKL reverse signalling. | Ikebuchi, Y., et al. 2018. Nature. 561: 195-200. PMID: 30185903
- RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. | Infante, M., et al. 2019. J Exp Clin Cancer Res. 38: 12. PMID: 30621730
- Targeting the RANKL/RANK/OPG Axis for Cancer Therapy. | Ming, J., et al. 2020. Front Oncol. 10: 1283. PMID: 32850393
- RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target. | Honma, M., et al. 2021. Pharmacol Ther. 218: 107682. PMID: 32956720
- Mechanisms of RANKL delivery to the osteoclast precursor cell surface. | Honma, M., et al. 2021. J Bone Miner Metab. 39: 27-33. PMID: 33047191
- RANKL and osteoimmunology in periodontitis. | Tsukasaki, M. 2021. J Bone Miner Metab. 39: 82-90. PMID: 33070252
- An Overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand RANKL and related nutritional interventions. | Ilchovska, DD. and Barrow, DM. 2021. Autoimmun Rev. 20: 102741. PMID: 33340772
- RANKL as the master regulator of osteoclast differentiation. | Takayanagi, H. 2021. J Bone Miner Metab. 39: 13-18. PMID: 33385253
- Role of RANKL in cancer development and metastasis. | Okamoto, K. 2021. J Bone Miner Metab. 39: 71-81. PMID: 33387063
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RANKL Antibody (12A380) | sc-59982 | 100 µg/ml | $322.00 | |||
RANKL Antibody (12A380) PE | sc-59982 PE | 100 tests in 2 ml | $349.00 |